Hepion Pharma edges up on starting liver disease treatment trial

Hepion Pharmaceuticals

31/08/2022 13:49

** Shares of Hepion Pharmaceuticals Inc  HEPA.O  rise 3% to
$0.67 premarket
    ** HEPA says it screened the first subject in a mid-stage
trial of its lead drug candidate, rencofilstat, for the
treatment of a chronic liver disease  urn:newsml:reuters.com:*:nGNX9pY3sH
    ** Trial of the drug for non-alcoholic steatohepatitis
(NASH) to include 336 subjects dosed for 12 months - company
    ** NASH is caused by a build-up of fat in the liver which
leads to liver inflammation and scarring; there is no
FDA-approved treatment for the disease yet
    ** As of last close, stock was down 43% YTD 

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))